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To the Editor: A 59-year-old healthy man presented
for evaluation of new-onset aquagenic pruritus. He
started testosterone replacement therapy (200 mg
daily) 7 months before presentation for low
testosterone level of unknown cause; testicular
biopsy at that time revealed normal findings. Four
months after beginning testosterone replacement, he
noticed generalized intense burning and pruritus,
specifically during and after showering, without
evidence of rash. Empiric use of emollients and
antifungal cream did not alleviate the pruritus. He
could not tolerate antihistamines because of drows-
iness. On evaluation, his full-body skin examination
revealed normal findings. This history and examina-
tion are consistent with aquagenic pruritus, which
typically presents without cutaneous signs.1 Because
aquagenic pruritus is most often associated with
polycythemia vera (PCV),2 hematologic studies wereFig 1. Aquagenic pruritus associated with testoste
hematocrit level, and testosterone dosage.
Open access under CC BY-NC-ND license.performed, revealing an elevated hematocrit of
51.2%, notably higher than his normal baseline of
46.5%. The remainder of his complete blood cell
count and differential, renal and liver function tests,
antinuclear antibody, and thyroid studies were
normal.
Because the aquagenic pruritus tightly coincided
with the initiation of his testosterone replacement
therapy, the patient’s testosterone dose was tapered
to 50%, which resulted in significant improvement in
his symptoms; his hematocrit also normalized to
baseline levels (Fig 1). Given that his erythrocytosis
and his symptoms were improving, the patient
was recommended to continue routine monitoring
of his hematocrit levels and did not undergo
further diagnostic evaluation for hematologic
malignancy.
Although most patients with aquagenic pruritus
do not have underlying disease, when associated
with systemic conditions, PCV is diagnosed in
approximately 30% of cases of aquagenic pruritus.3,4
Aquagenic pruritus is reported by approximately 5%
to 69% of patients with PCV and may precede the
diagnosis of PCV by many years.3,4 Aquagenic pru-
ritus may also occur in the setting of myelofibrosis,
malignancy, medications (bupropion, antimalarials),
and lactose intolerance.4 However, little is known
about the mechanism or pathophysiology of
aquagenic pruritus. One study looking at skin
biopsy specimens taken from patients with PCV
and aquagenic pruritus demonstrated increased
skin mast cells, mononuclear cells, and eosinophils.3rone-induced erythrocytosis: clinical course,
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may be functionally different from those in healthy
control subjects. Specifically, release of increased
levels of pruritogenic factors by mast cells, including
interleukin-31, histamine, and leukotrienes, is
postulated to mediate pruritus. Homozygous
JAK2V617F mutationeone of the mutations that
causes PCVehas also been correlated with a higher
incidence of pruritus among 58 patients with
PCV (69% vs 38%, P ¼ .04), compared with
heterozygotes.3
Testosterone replacement therapy has been
associated with erythrocytosis because of its ability
to stimulate erythropoietin and its direct effect
on erythroblasts in bone marrow.5 Increase in
hemoglobin is the most common adverse effect of
testosterone treatment in men.5
To our knowledge, this is the first report of
testosterone-induced erythrocytosis associated with
PCV-like aquagenic pruritus. This case highlights the
concept that erythrocytosis in a setting other than
PCVmay also cause aquagenic pruritus and common
pathophysiologic mechanisms may contribute to
aquagenic pruritus in both conditions; lowering the
hematocrit by removing or reducing the cause of
erythrocytosis may reverse the symptoms.
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